Tag Archives: sHTG

Ascletis Doses First Patient in Ph3; Arrowhead ESC 2026 Investor Event; Cytokinetics ACACIA-HCM Primary Results; Amgen Repatha Sub-Analyses; Alnylam Vutrisiran Sub-Analysis; Lilly 52-Week Taltz + Tirzepatide Data

A series of cardiometabolic-related news items has been observed from Ascletis Pharma, Arrowhead Pharmaceuticals, Cytokinetics, Amgen, Alnylam, and Lilly. Below, FENIX provides highlights and insights for the respective news items, including a projected approval timeline for Ph3 oral AOM development.

This content is for Read Less members only.
Already a member? Log in here

Viking Ph1 DACRA Study; Lilly Collaborates with Oura; Pivot Patch Pump US Launch; Wave Initiates Ph2a MAD INLIGHT Study; Wegovy FlexTouch Label Update; Tryngolza sHTG US Approval

A series of cardiometabolic-related news items has been observed from Viking Therapeutics, Lilly/Oura, Modular Medical, Wave Life Sciences, Novo Nordisk, and Ionis Pharmaceuticals. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here